Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 

Click here to view
our current issue



 
 

Friends or Foes?

Isobel Finnie and Joanna Rowley at Haseltine Lake provide solutions to issues surrounding policy- and subject matter-based exclusions from patentability that are frequently encountered by pharmaceutical and biotechnology companies.

By Isobel Finnie and Joanna Rowley at Haseltine Lake (October 2018)

Keywords: Diagnosis, Patentability, Return on investment

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | caitlin@samedanltd.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |